History of thromboembolic or cerebrovascular events ? months prior to starting study treatment, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis or pulmonary emboli History of arterial thrombotic or embolic events (within months prior to study entry) Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within months of start of study registration History of thromboembolic or cerebrovascular events ? months prior to starting study treatment, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis or pulmonary emboli. Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident, deep vein thrombosis or pulmonary embolus within months of informed consent Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within months of start of study treatment within months of informed consent Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within months of start of study treatment within months of informed consent Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) or deep venous thrombosis (DVT) within months of informed consent\r\n* Tumor or bland thrombus in hepatic vasculature is not a contraindication provided hepatic function criteria are met Significant thrombotic or embolic events within weeks prior to study day ; significant thrombotic or embolic events include but are not limited to stroke or transient ischemic attack (TIA); catheter-related thrombosis is not a cause for exclusion; diagnosis of deep vein thrombosis or pulmonary embolism is allowed if it occurred > weeks prior to study day and the patient is asymptomatic and stable on anti-coagulation therapy FOR ALL PHASES (Ib AND II): Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within months before the start of study medication Subjects diagnosed with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within months of start of study treatment Thrombotic or embolic events; Thrombotic, embolic, venous or arterial events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within months of informed consent Arterial thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), or venous pulmonary embolism within months before the start of study treatment; venous thrombotic events such as deep vein thrombosis within months before the start of study treatment Arterial thrombotic or embolic events such as cerebrovascular accident (including ischemic attacks) or hemoptysis within months before the first dose of study drug. Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic, attacks, deep vein thrombosis (DVT) within the past months SORAFENIB\r\n* Major surgery, open biopsy, or significant traumatic injury within days\r\n* Non-healing wound, ulcer, or bone fracture\r\n* Thrombotic or embolic venous or arterial events, such as cerebrovascular accident, including transient ischemic attacks, arterial thrombosis, deep vein thrombosis and pulmonary embolism within the past months\r\n* Upper Extremity/Line associated DVTs which are adequately treated (line removed and/or patient anticoagulated) are eligible\r\n* Uncontrolled hypertension\r\n* Active bleeding during screening\r\n* Hypersensitivity to sorafenib Significant thrombotic or embolic events within months prior to study day ; significant thrombotic or embolic events include but are not limited to stroke or transient ischemic attack (TIA); catheter-related thrombosis is not a cause for exclusion; diagnosis of deep vein thrombosis or pulmonary embolism is allowed if the patient is clinically stable and has completed or is on stable anti-coagulation therapy Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the months before enrollment Any documented history of clinically identifiable thrombotic, embolic, venous, or arterial events such as cerebrovascular accident, transient ischemic attack, deep vein thrombosis, or pulmonary embolism within months prior to initiating study treatment\r\n* Note: Patients with an asymptomatic catheter-related thrombus or a tumor-associated thrombus of locally-involved vessels or with incidental asymptomatic filling defects identified on imaging are not excluded Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within months of start of study treatment Any documented history of thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident, transient ischemic attack, deep vein thrombosis, or pulmonary embolism within months prior to initiating study treatment\r\n* Note: patients with a tumor-associated thrombus of locally-involved vessels should not be excluded from participating in the study Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past months Arterial thrombotic or embolic events such as a myocardial infarction or cerebrovascular accident (including transient ischemic attacks) within the months prior to initiation of treatment; incidental clinically insignificant embolic phenomena that do not require anti-coagulants are not excluded; also, tumor-associated thrombus of locally-involved vessels does not count as an exclusion criterion Sorafenib\r\n* Major surgery, open biopsy, or significant traumatic injury within days\r\n* Non-healing wound, ulcer, or bone fracture\r\n* Thrombotic or embolic venous or arterial events, such as cerebrovascular accident, including transient ischemic attacks, arterial thrombosis, deep vein thrombosis and pulmonary embolism within the past months\r\n* Uncontrolled hypertension\r\n* Active bleeding during screening\r\n* Hypersensitivity to sorafenib Thrombolic or embolic events (except deep vein thrombosis [DVT] or pulmonary embolus) such as a cerebrovascular accident including transient ischemic attacks within the past months Arterial or venous thrombotic events or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within months before randomization Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within months of start of study treatment Any documented history of clinically significant thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident, transient ischemic attack, deep vein thrombosis, or pulmonary embolism necessitating therapeutic anticoagulation within months prior to initiating study treatment; Note: Patients with a tumor-associated thrombus of locally-involved vessels should not be excluded from participating in the study Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within months before registration Patients with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within months of the study registration Significant thrombotic or embolic events within months prior to study day ; significant thrombotic or embolic events include but are not limited to stroke or transient ischemic attack (TIA); catheter-related thrombosis is not a cause for exclusion; diagnosis of deep vein thrombosis or pulmonary embolism is allowed if it occurred > months prior to study day and the patient has completed or is on stable anti-coagulation therapy Patients with a history of thrombotic or embolic events within the last six months such as a cerebrovascular accident (including transient ischemic attacks), pulmonary embolism Patients with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks [TIAs]) within months before randomization Arterial or venous thrombotic or embolic events such as cerebral vascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within months before randomization (except for adequately treated catheter-related venous thrombosis occurring within months before randomization). Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past months Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within months of start of study treatment. Any history of thrombotic cerebrovascular accident or other arterial thrombosis Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past months History of thromboembolic or cerebrovascular events =< months prior to starting study treatment, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis or pulmonary emboli Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within months of study treatment start Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within months of informed consent Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism =< months prior to randomization Significant thrombotic or embolic events within weeks prior to study day ; significant thrombotic or embolic events include but are not limited to stroke or transient ischemic attack (TIA); catheter-related thrombosis is not a cause for exclusion; diagnosis of deep vein thrombosis or pulmonary embolism is allowed if it occurred > weeks prior to study day and the patient is asymptomatic and stable on anti-coagulation therapy Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism =< months prior to registration Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the months before start of study medication (except for adequately treated catheter-related venous thrombosis occurring more than month before the start of study medication) Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within months of informed consent Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within months of start of study treatment Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past months History of arterial thrombotic or embolic events (within months prior to study entry) Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) within months of informed consent Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) within months of informed consent Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within months before the start of study medication. Arterial thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), or pulmonary embolism within the months before start of FOLFIRI Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past months Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past months; hepatic portal vein thrombus is not considered an exclusion criterion Thrombotic or embolic events such as cerebrovascular accident, deep vein thrombosis or pulmonary embolism. History of transient ischemic attack is allowed. Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within months of study registration. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the months before start of study medication (except for adequately treated catheter-related venous thrombosis occurring more than month before the start of study medication). Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within months before start of study treatment. However, if a patient has recovered to ECOG performance status of ? he/she may be enrolled provided that other eligibility criteria are met Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within months of start of study treatment Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within months of start of study treatment Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism that have initiated within months of start of study treatment; stable, persistent events under appropriate management diagnosed > months prior to treatment are allowed at the discretion of the investigator Arterial or venous thrombotic or embolic events Have had arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within months prior to the initiation of study treatment. Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past months History of arterial or venous thrombotic/embolic events =< months prior to registration Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within months before the start of study medication Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within months of informed consent; Note: subjects with recent deep vein thrombosis (DVT) who have been treated with therapeutic anticoagulating agents for at least weeks prior to study treatment are eligible Thrombolytic, embolic, venous, or arterial events such as cerebrovascular accident including transient ischemic attacks within the past months Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past months Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past months Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past months Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past months Have had arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within months prior to the initiation of study treatment Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within months of start of study treatment within months of informed consent